One of Wales’ leading life sciences firms, Diurnal, is set to be acquired by a US firm in a £48.3m cash deal.
Subject to shareholder approval the Cardiff-based Alternative Investment Market-listed firm will be acquired by Neurocrine, a neuroscience-focused biopharmaceutical company, with sales of $1bn.
Diurnal, which is headquartered in Cardiff and employs 33, is a pharmaceutical group targeting patient needs in chronic endocrine (hormonal) diseases.